...Yun Jeong Hong; Hyun Jeong Han; Young Chul Youn; Kyung Won Park; Dong Won Yang; SangYun Kim; Hwa Jung Kim; Hyung-Ji Kim; Yoojin Lee; Miseon Kwon; Jae-Hong Lee; on behalf of the ODESA study (Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23 mg) Background...

... in the pathogenesis and progression of neurodegenerative diseases. Methods: In this study, we tested the hypothesis that donepezil would attenuate central inflammation and oxidative damage and improve memory deficit in high-fat diet (HFD)-fed mice. After 16 weeks on a HFD, C57BL/6J mice were given either donepezil (3...

...: This study is a post hoc analysis of a double-blind clinical trial. Donepezil was used as the standard control treatment. Outcomes included score changes from baseline to week 24 on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog), a modified 20-item Activities of Daily Living Scale...

...Akiko Ishiwata; Sunao Mizumura; Masahiro Mishina; Mineo Yamazaki; Yasuo Katayama Background/Aims: Donepezil is an acetylcholinesterase inhibitor used to treat Alzheimer's disease (AD). In this study, we used a voxel-based specific regional analysis system for AD (VSRAD) to analyze the hippocampal...

...Nirmal Sonali; Manjari Tripathi; Rajesh Sagar; Thirumurthy Velpandian; Vivekanandhan Subbiah Aim: The impact of CYP2D6 and CYP3A4 polymorphism on the steady-state plasma concentrations and therapeutic outcome of donepezil monotherapy and combination therapy in Alzheimer's disease (AD) patients...

...Manabu Ikeda; Etsuro Mori; Kenji Kosaka; Eizo Iseki; Mamoru Hashimoto; Noriyuki Matsukawa; Kazutaka Matsuo; Masaki Nakagawa; on behalf of the Donepezil-DLB Study Investigators Background/Aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients...

...Rachelle S. Doody; David S. Geldmacher; Martin R. Farlow; Yijun Sun; Margaret Moline; Joan Mackell Background/Aims: A large multicenter trial of donepezil 23 mg/day versus donepezil 10 mg/day for moderate-to-severe Alzheimer’s disease allowed patients taking concomitant memantine. We evaluated...

... comparing it with donepezil, an anticholinesterase drug used with some benefit to treat BPSD. Methods and Findings: The study was a double-blind parallel-group placebo-controlled randomized trial across 3 specialist old age psychiatry centres in England. Participants had probable or possible Alzheimer’s...

... across three centres, New York, Sydney and Manchester) with all the patients receiving donepezil and the caregivers randomised to a caregiver intervention or treatment as usual. Results: There were few differences between countries in the main outcome measures, and no differences between the treatment...

..., 8 mg RSG XR or 10 mg donepezil (control). Coprimary endpoints were change from baseline to week 24 in the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-Cog) score, and week 24 Clinician’s Interview-Based Impression of Change plus caregiver input (CIBIC+). Results: At week 24...

... an assessment of donepezil treatment on SIB scores, and to potentially identify a cognitive transition point associated with predicted functional disability. Methods: The study comprised 290 patients with MSAD (standardized Mini-Mental State Examination score, 5–17) treated with donepezil 5–10 mg/day...

... suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD). Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10–27] were pooled from 3 randomized, double-blind placebo-controlled...

... the degree of satisfaction with the main available drug treatments in monotherapy for AD from this point of view. Methods: A cross-sectional, multicentre study of patients with possible/probable AD according to DSM-IV/NINCDS-ADRDA criteria, on monotherapy with donepezil, galantamine, rivastigmine...

... and efficacy of donepezil in community-dwelling Japanese patients with severe Alzheimer’s disease (AD). Methods: 189 patients were enrolled from the double-blind study into a 52-week, open-label extension study. After a 2- to 8-week washout, donepezil was escalated within 6 weeks to 10 mg/day. Main outcomes...

...) might predict cognitive changes in response to donepezil treatment, as assessed in terms of the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), and in relation to the severity of subcortical hyperintensities (SH). Method: Forty-one patients with Alzheimer’s disease (AD) were treated...

...Vesna Jelic; Anders Haglund; Jan Kowalski; Sven Langworth; Bengt Winblad Background/Aims: Our objective was to define clinically meaningful outcomes in donepezil versus placebo treatment in severe Alzheimer’s disease (AD) and to describe characteristics of responders. Methods: Analyses were...

...Carina Wattmo; Oskar Hansson; Åsa K. Wallin; Elisabet Londos; Lennart Minthon Background/Aims: To build and analyze regression models predicting (1) the long-term cognitive outcome in donepezil-treated patients with Alzheimer’s disease, and (2) the short-term (6 months) cognitive impact...

... of controversy. In order to address this issue, we investigated the effects of ApoE genotype on the clinical response to donepezil in patients with mild to moderate AD. Methods: An open study was carried out in 51 patients with probable AD who were treated with 5–10 mg of donepezil per day for 48 weeks. Results...

... and tolerability of donepezil in severe Alzheimer’s disease (AD). Methods: Patients with severe AD (Mini-Mental State Examination score 1–12; modified Hachinski Ischemic Score ≤6; Functional Assessment Staging ≧6) were enrolled in this study in Japan. A total of 325 patients were randomized to donepezil 5 mg/day...

...Daniel Saumier; Susan Murtha; Howard Bergman; Natalie Phillips; Victor Whitehead; Howard Chertkow Objectives: To examine whether the presence of domain-specific cognitive impairments would predict a response to donepezil medication in patients with mild-to-moderate Alzheimer disease (AD). Methods...